Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 81 P664 | DOI: 10.1530/endoabs.81.P664

1Università “Federico II” di Napoli, Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Naples, Italy; 2Università degli Studi di Torino, SC Endocrinologia, Diabetologia e Metabolismo U, Dipartimento di Scienze Mediche, Turin, Italy; 3IRCCS Policlinico San Martino Università di Genova, Dipartimento di Medicina Interna & Specialità Mediche (DiMI), Genoa, Italy; 4Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Endocrinology Unit, Milan, Italy; 5Università degli Studi di Messina, Dipartimento di Patologia Umana dell’adulto e dell’età evolutiva, Messina, Italy; 6Universitàdegli Studi di Palermo, Dipartimento promise, UOC di Endocrinologia e Malattie metaboliche, Palermo, Italy; 7University-Hospital of Padova, Endocrinology Unit, Department of Medicine, DIMED, Padua, Italy; 8Università degli Studi di ROMA “Sapienza“, Dipartimento di MEDICINA SPERIMENTALE, Rome, Italy; 9Università di Catania, UOC di Andrologia e Endocrinologia, Policlinico “G. Rodolico“, Dipartimento di Medicina Clinica e sperimentale, Catania, Italy; 10University of Naples Federico II, Department of Neuroscience, Naples, Italy; 11“Federico II” University, Unesco Chair for Health Education and Sustainable Development, Naples, Italy


Over the last two years, COVID-19 outbreak and lockdown have exerted a remarkable psychological burden in the general population. Such an impact is supposed to be even worse in acromegaly, known to induce a severe psychological impairment due to its somatic disfigurements and systemic comorbidities. The current observational study aimed at investigating the impact of COVID-19 outbreak and lockdown on psychological health in acromegalic patients as compared to non-acromegalic healthy control population. During the last three weeks of lockdown, 246 patients (110 males, 136 females, age 51.4 ± 11.7 years) with history of acromegaly or active acromegaly under treatment from 9 Italian acromegaly referral centers and 246 age, gender, and marital status-matched controls were telematically administered several psychological questionnaires, aiming at evaluating the spectrum of anxiety (GAD-7) and depression (PHQ-9), and perceived stress (PSS). For all questionnaires, higher score indicated greater psychological impairment. A questionnaire evaluating quality of life in acromegaly, AcroQol, for which the higher score indicates a better quality of life, was administered exclusively to patients. Compared to controls, patients showed a significantly higher prevalence of moderate (P=0.046) and severe depression (P=0.015), and severe anxiety (P=0.024). Both in patient and controls, females showed higher scores in the entire series of psychological tests performed compared to males (P<0.001). Moreover, male patients showed significantly higher anxiety (P=0.001), and depression (P<0.001) scores, whereas female patients showed higher anxiety (P=0.003) and perceived stress (P=0.037) scores compared to respective controls. Glucocorticoid replacement (GR) therapy was significantly associated with higher scores of anxiety (P=0.01), depression (P=0.037), and perceived stress (P=0.003), and lower score of AcroQol (P=0.038). Patients with anxiety, depression, and perceived stress were mostly females (P<0.05), and patients with anxiety and perceived stress were also associated with low-grade instruction (P<0.01) and GR therapy (P<0.01). In conclusions, patients who experienced acromegaly had a greater risk of depressive and anxiety disorders as well as perceived stress compared to controls during COVID-19 outbreak and lockdown, thus suggesting the importance of a strict psychological monitoring.

Volume 81

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.